SPDR S&P Biotech ETF Rating $90.29 +0.39 (+0.43%) Closing price 04:10 PM EasternExtended Trading$90.15 -0.14 (-0.15%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.72Holdings in XBI have an aggregate rating of Moderate Buy based on 485 analyst ratings issued in the past year covering 25 companies (57.1% of the portfolio).XBI Aggregate Price Target$90.29High Prediction$90.29Average Prediction$90.29Low Prediction$90.29Holdings in XBI have an aggregate price target of $90.29 and a range of $90.29 to $90.29 covering 25 companies (57.1% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.61%ALNYAlnylam Pharmaceuticals$454.18+0.7%4.0548 of 5 stars2.85$405.33 -10.8%263.06%HALOHalozyme Therapeutics$73.18+0.3%4.6462 of 5 stars2.18$67.11 -8.3%11News CoveragePositive News3.06%INSMInsmed$134.53+1.8%3.7704 of 5 stars2.94$132.57 -1.5%172.92%INCYIncyte$84.84+1.0%4.6678 of 5 stars2.33$81.60 -3.8%182.67%UTHRUnited Therapeutics$305.35-1.3%4.9874 of 5 stars2.69$382.00 25.1%13Positive NewsAnalyst Revision2.60%REGNRegeneron Pharmaceuticals$586.96-0.1%4.8566 of 5 stars2.81$817.67 39.3%27Trending NewsAnalyst Forecast2.54%GILDGilead Sciences$113.92-0.7%4.9859 of 5 stars2.88$115.39 1.3%26Trending News2.53%ABBVAbbVie$208.24-0.1%4.7028 of 5 stars2.96$214.95 3.2%27Trending NewsAnalyst Forecast2.52%NBIXNeurocrine Biosciences$138.13+0.9%4.8625 of 5 stars2.86$159.50 15.5%21News CoveragePositive News2.46%BIIBBiogen$136.36-0.3%4.809 of 5 stars2.34$185.74 36.2%32Positive News2.38%AMGNAmgen$287.97-0.6%4.7436 of 5 stars2.33$304.43 5.7%21Positive NewsAnalyst Forecast2.37%MRNAModerna$25.10+1.5%4.5014 of 5 stars2.04$42.88 70.8%242.36%BBIOBridgeBio Pharma$49.59+1.5%4.293 of 5 stars3.00$61.35 23.7%172.36%BMRNBioMarin Pharmaceutical$58.66+2.1%4.9963 of 5 stars2.72$93.17 58.8%25Positive News2.28%MDGLMadrigal Pharmaceuticals$425.06+0.0%3.8643 of 5 stars2.90$459.25 8.0%10Analyst Forecast2.26%NTRANatera$163.04-1.6%3.1194 of 5 stars3.06$193.19 18.5%18Positive News2.13%EXELExelixis$38.51+0.4%4.8826 of 5 stars2.55$44.06 14.4%222.03%VRTXVertex Pharmaceuticals$389.08+0.5%4.9435 of 5 stars2.56$497.10 27.8%27Positive News1.93%EXASExact Sciences$46.71+1.3%4.9353 of 5 stars2.91$67.05 43.5%23Positive News1.70%ROIVRoivant Sciences$11.99+1.3%3.2013 of 5 stars3.25$16.50 37.6%41.57%CYTKCytokinetics$37.83-0.9%3.6192 of 5 stars2.93$71.58 89.2%15News CoveragePositive News1.52%CRSPCRISPR Therapeutics$53.53-2.5%3.53 of 5 stars2.50$71.60 33.8%16Positive News1.51%IONSIonis Pharmaceuticals$42.75+1.4%4.6202 of 5 stars2.86$59.64 39.5%14News CoverageAnalyst ForecastOptions VolumeAnalyst Revision1.37%RVMDRevolution Medicines$38.04+2.0%4.3959 of 5 stars3.00$69.92 83.8%13Positive News1.37%RNAAvidity Biosciences$47.82+1.6%2.9738 of 5 stars3.06$67.00 40.1%18Positive News This page (NYSEARCA:XBI) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access